Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: A randomized, single-dose, two-period, two-sequence crossover study

Clinical Therapeutics

Volumn 30, Issue 10, 2008, Pages 1844-1851

  Srichaiya, Arunee ^a   Longchoopol, Chaowanee ^a   Oo Puthinan, Sarawut ^a   Sayasathid, Jarun ^a   Sripalakit, Pattana ^a   Viyoch, Jarupa ^a  

^a NARESUAN UNIVERSITY   (Thailand)

Author keywords

bioequivalence; high performance liquid chromatography ultraviolet; HPLC UV; lamotrigine; Thai male volunteers

Indexed keywords

GENERIC DRUG; LAMIDUS; LAMOTRIGINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THAILAND; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANTICONVULSANTS; AREA UNDER CURVE; CROSS-OVER STUDIES; HALF-LIFE; HUMANS; MALE; THAILAND; THERAPEUTIC EQUIVALENCY; TRIAZINES; YOUNG ADULT;

EID: 55949130424     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.10.018     Document Type: Article

References (27)

1. Backonja M. Neuromodulating drugs for the symptomatic treatment of neuropathic pain. Curr Pain Headache Rep 8 (2004) 212-216
2. Pappagallo M. Newer antiepileptic drugs: Possible uses in the treatment of neuropathic pain and migraine. Clin Ther 25 (2003) 2506-2538
3. Jensen T.S. Anticonvulsants in neuropathic pain: Rationale and clinical evidence. Eur J Pain 6 Suppl A (2002) 61-68
4. Barbosa L., Berk M., and Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 64 (2003) 403-407
5. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder. Calabrese J.R., Suppes T., Bowden C.L., et al. Lamictal 614 Study Group. J Clin Psychiatry 61 (2000) 841-850
6. for the Lamictal vs. Carbamazepine Study Group. Nieto-Barrera M., Brozmanova M., Capovilla G., et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res 46 (2001) 145-155
7. Messenheimer J., Mullens E.L., Giorgi L., and Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 18 (1998) 281-296
8. Stefani A., Spadoni F., and Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 37 (1998) 83-91
9. Stefani A., Hainsworth A.H., Spadoni F., and Bernardi G. On the inhibition of voltage activated calcium currents in rat cortical neurones by the neuroprotective agent 619C89. Br J Pharmacol 125 (1998) 1058-1064
10. Goa K.L., Ross S.R., and Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46 (1993) 152-176
11. Stefan H., and Feuerstein T.J. Novel anticonvulsant drugs. Pharmacol Ther 113 (2007) 165-183
12. Lamictal (lamotrigine) tablets [drug description] (March 1, 2008). http://www.rxlist.com/cgi/generic/lamotrigine.htm Accessed
13. Peck A.W. Clinical pharmacology of lamotrigine. Epilepsia 32 Suppl 2 (1991) S9-S12
14. Cohen A.F., Land G.S., Breimer D.D., et al. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans. Clin Pharmacol Ther 42 (1987) 535-541
15. Sabers A., Ohman I., Christensen J., and Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 61 (2003) 570-571
16. Reisman D.A. Payment for health in Thailand. Int J Soc Econ 26 (1999) 609-641
17. Instruction for the In Vivo Bioequivalence Study Protocol Development (September 24, 2008). http://www.app1.fda.moph.go.th/drug/zone_bioequivalence/ser001.asp Accessed
18. Malik S., Arif H., and Hirsch L.J. Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders. Expert Rev Neurotherapeutics 6 (2006) 1609-1627
19. FDA Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies (March 1, 2008). http://www.fda.gov/CDER/guidance/5194fnl.htm Accessed
20. Guidance for Industry: Bioanalytical method validation (March 25, 2006). http://www.fda.gov/cder/guidance/4252fnl.pdf Accessed
21. GlaxoSmithKline Clinical Trial Register: Lamotrigine studies (March 1, 2008). Accessed http://ctr.gsk.co.uk/Summary/lamotrigine/studylist.asp
22. Sane R.T., Francis M., and Deo A. Bioequivalence study of lamotrigine tablets in healthy male human volunteers. Indian Drugs 35 (1998) 570-573
23. Richens A. Pharmacokinetics of lamotrigine. In: Richens A. (Ed). Clinical Update on Lamotrigine: A Novel Antiepileptic Agent (1992), Wells Medical Limited, Kent, UK 21-27
24. Ramsay R.E., Pellock J.M., Garnett W.R., et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 10 (1991) 191-200
25. Cheng C.L., Chou C.H., and Hu O.Y. Determination of lamotrigine in small volumes of plasma by highperformance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 817 (2005) 199-206
26. Croci D., Salmaggi A., de Grazia U., and Bernardi G. New high-performance liquid chromatographic method for plasma/serum analysis of lamotrigine. Ther Drug Monit 23 (2001) 665-668
27. Castel-Branco M.M., Almeida A.M., Falcão A.C., et al. Lamotrigine analysis in blood and brain by highperformance liquid chromatography. J Chromator B Biomed Sci Appl 755 (2001) 119-127